---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: American hospital formulary service (AHFS), or other drug classification"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: American hospital formulary service (AHFS), or other drug classification. Topics: WHO INN functional description: apolipoprotein L1 function inhibitor and EMA classification: apolipoprotein L1 inhibitors. 2 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/american-hospital-formulary-service-ahfs-or-other-drug-classification"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: American hospital formulary service (AHFS), or other drug classification

<a id="heading-2.1.2.4"></a>

## 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

### WHO INN functional description: apolipoprotein L1 function inhibitor

> “apolipoprotein L1 (APOL1) function inhibitor”

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.4-3"></a>

### EMA classification: apolipoprotein L1 inhibitors

> “This medicine belongs to the class of apolipoprotein L1 inhibitors.”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

| Field | Quoted record |
| --- | --- |
| Therapeutic area | “Uro-nephrology” |

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
